SequelSEC

Edesa Biotech, Inc. EDSA

Pharmaceutical Preparations · CIK 0001540159 · Fiscal year ends 0930

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2021-09-30
Operating income
-$23.68M
Fiscal year ended 2021-09-30
Free cash flow
-$13.67M
Fiscal year ended 2021-09-30

Edesa Biotech, Inc. (EDSA) reported revenue of $0 and net income of -$13.34M for the fiscal year ended 2021-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Edesa Biotech, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Edesa Biotech, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-30
Revenue$0
Cost of revenue$0
Gross profit$0
Operating income-$23.68M
Net income-$13.34M
Research & development$17.95M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$800
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$5.73M
Selling & marketingUnavailable

Balance

Edesa Biotech, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-30
Cash & equivalents$7.84M
Total assets$14.58M
Current assets$12.09M
Total liabilities$1.53M
Current liabilities$1.46M
Total equity incl. NCI$13.06M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$3.30M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Edesa Biotech, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-30
Operating cash flow-$13.66M
Capital expenditures$6.15K
Investing cash flow-$6.15K
Financing cash flow$14.17M
Net change in cash$625.56K
Stock-based compensation$3.20M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$118.79K

Derived

Edesa Biotech, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-30
Free cash flow-$13.67M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio8.29x
Revenue YoY growth-100.0%
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open EDSA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-Q · Filed 2026-02-13View SEC filing
10-K · Filed 2025-12-12View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.